5-Lipoxygenase contributes to the progression of hepatocellular carcinoma

Molecular Medicine Reports

Volumn 4, Issue 6, 2011, Pages 1195-1200

  Xu, Xi Ming ^a   Deng, Jun Jian ^a   Yuan, Guang Jin ^b   Yang, Fang ^c   Guo, Hong Ting ^a   Xiang, Miao ^a   Ge, Wei ^a   Wu, Yao Gui ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Cancer Center   (China)

^c WUHAN UNIVERSITY   (China)

Author keywords

5 lipoxygenase; Hepatocellular carcinoma; Zileuton

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; DIETHYLNITROSAMINE; MESSENGER RNA; ZILEUTON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER NODULE; MALE; NICK END LABELING; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; APOPTOSIS; ARACHIDONATE 5-LIPOXYGENASE; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DIETHYLNITROSAMINE; HEP G2 CELLS; HUMANS; HYDROXYUREA; LIPOXYGENASE INHIBITORS; LIVER NEOPLASMS; RATS; RNA, MESSENGER;

RATTUS;

EID: 80053110423     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.547     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
2. McGlynn KA and London WT: Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 19: 3-23, 2005. (Pubitemid 40331495)
3. Altekruse SF, McGlynn KA and Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485-1491, 2009.
4. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma.Lancet 362: 1907-1917, 2003. (Pubitemid 37518510)
5. Lau WY, Lai EC and Lau SH: The current role of neoadjuvant/adjuvant/ chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 8: 124-133, 2009.
6. Goossens L, Pommery N and Henichart JP: COX-2/5-LOX dual actinganti-inflammatory drugs in cancer chemotherapy. Curr Top Med Chem 7: 283-296, 2007. (Pubitemid 46358662)
7. Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC and Kelloff GJ: Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 8: 467-483, 1999. (Pubitemid 29230553)
8. Ding XZ, Hennig R and Adrian TE: Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. Mol Cancer 2: 10, 2003.
9. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG and Mukhtar H: Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 91: 737-743, 2001. (Pubitemid 32173298)
10. Hennig R, Grippo P, Ding XZ, Rao SM, Buchler MW, Friess H, Talamonti MS, Bell RH and Adrian TE: 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res 65: 6011-6016, 2005. (Pubitemid 40994383)
11. Ohd JF, Nielsen CK, Campbell J, Landberg G, Löfberg H and Sjölander A: Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 124: 57-70, 2003. (Pubitemid 36055339)
12. Yoshimura R, Matsuyama M, Tsuchida K, Kawahito Y, Sano H and Nakatani T: Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. J Urol 170: 1994-1999, 2003. (Pubitemid 37254995)
13. Li N, Sood S, Wang S, Fang M, Wang P, Sun Z, Yang CS and Chen X: Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 11: 2089-2096, 2005. (Pubitemid 40471876)
14. Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z, Beer DG, Giordano TJ, Lin Y, Shih WC, et al: Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res 10: 6703-6709, 2004. (Pubitemid 39346568)
15. Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Martínez A and Mulshine JL: Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 97: 806-813, 1996. (Pubitemid 26057100)
16. Ghosh J: Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. Biochem Biophys Res Commun 307: 342-349, 2003.
17. Ding XZ, Iversen P, Cluck MW, Knezetic JA and Adrian TE: Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun 261: 218-223, 1999. (Pubitemid 29371644)
18. Gunning WT, Kramer PM, Steele VE and Pereira MA: Chemo-prevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res 62: 4199-4201, 2002. (Pubitemid 34827271)
19. Wenger FA, Kilian M, Achucarro P, Heinicken D, Schimke I, Guski H, Jacobi CA and Müller JM: Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology 2: 54-60, 2002. (Pubitemid 34639103)
20. Soumaoro LT, Iida S, Uetake H, Ishiguro M, Takagi Y, Higuchi T, Yasuno M, Enomoto M and Sugihara K: Expression of 5-lipoxygenase in human colorectal cancer. World J Gastroenterol 12: 6355-6360, 2006. (Pubitemid 44712419)
21. Nielsen CK, Ohd JF, Wikström K, Massoumi R, Paruchuri S, Juhas M and Sjölander A: The leukotriene receptor CysLT1 and 5-lipoxygenase are upregulated in colon cancer. Adv Exp Med Biol 525: 201-204, 2003. (Pubitemid 36667734)
22. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, Clergue F, Poupon R, Barbu V and Rosmorduc O: Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41: 307-314, 2005. (Pubitemid 40165374)
23. Denda A, Endoh T, Tang Q, Tsujiuchi T, Nakae D and Konishi Y: Prevention by inhibitors of arachidonic acid cascade of liver carcinogenesis, cirrhosis and oxidative DNA damage caused by a choline-deficient, L-amino acid-defined diet in rats. Mutat Res 402: 279-288, 1998. (Pubitemid 28440284)
24. Tang DG, Chen YQ and Honn KV: Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA 3: 5241-5246, 1996. (Pubitemid 26159433)
25. Ghosh J and Myers CE: Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 5: 13182-13187, 1998. (Pubitemid 28509545)